Innovative Diagnostic Technology Braingaze has developed patented eye movement technology to detect and diagnose cognitive disorders like ADHD and Alzheimer's, offering a unique solution that appeals to clinics and healthcare providers seeking advanced diagnostic tools.

Growing Strategic Partnerships Recent collaboration with Tris Pharma and involvement in PepsiCo's Greenhouse Accelerator demonstrate Braingaze's ability to forge influential partnerships, opening avenues for expanding into larger healthcare and neurotechnology markets.

Expanding Digital Therapeutics With the launch of multiple cognitive therapy apps across platforms including Android, iOS, and Windows, Braingaze is positioned to capture a broader market seeking accessible, digital healthcare solutions for attention and cognitive disorders.

Funding and Investment The company has secured $1.6 million in funding, indicating investor confidence that can support scaling commercialization efforts and building relationships with clinics, hospitals, and pharmaceutical companies.

Market Differentiation As a spin-off from the University of Barcelona with a specialized team of scientists and AI experts, Braingaze offers differentiated, cutting-edge solutions that can be presented to health institutions and medical device distributors as a technologically advanced partner.